TXMD

#4492
TherapeuticsMD, Inc. - Common Stock
2.2 2 USD
0.00%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
2.22
2.22
Intervallo Annuale
0.99
2.94
Variazione giornaliera
0.00%
Variazione Mensile
+9.36%
Variazione di 6 mesi
-0.89%
Variazione Annuale
+111.43%
Chiusura Precedente
2.2 2
Open
2.2 2
Minimo
2.2 2
Massimo
2.2 2
Volume
3
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Therapeuticsmd, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Therapeuticsmd, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Therapeuticsmd, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Therapeuticsmd, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Therapeuticsmd, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Therapeuticsmd, Inc. current report, Q1 FY2026
8-K

2025

Annual report, FY2025
Therapeuticsmd, Inc. annual report, FY2025
10-K
Current report, Q4 FY2025
Therapeuticsmd, Inc. current report, Q4 FY2025
8-K
Current report, Q4 FY2025
Therapeuticsmd, Inc. current report, Q4 FY2025
8-K
Quarterly report, Q3 FY2025
Therapeuticsmd, Inc. quarterly report, Q3 FY2025
10-Q

Therapeuticsmd, Inc. current report, Q2 FY2012

Full document

Business Context and Reporting Period

This Form 8-K Current Report was filed by TherapeuticsMD, Inc. on May 16, 2012. The filing addresses corporate governance changes, specifically the election of a new Chairman of the Board.

Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance metrics.

Material Changes

  • Leadership Transition: On May 16, 2012, the Board of Directors elected Tommy G. Thompson as a member of the Board and named him Chairman.
  • Resignation: Robert G. Finizio resigned from his position as Chairman of the Board.
  • Continued Role: Robert G. Finizio will continue to serve as a director and as the Chief Executive Officer of the Company.
  • Term: Secretary Thompson will serve until the Company's next Annual Meeting of Shareholders or until his successor is duly elected and qualified.

Outlook, Risks, and Management Commentary

Management highlighted Secretary Thompson's extensive background, including his tenure as Secretary of the U.S. Department of Health & Human Services (2001-2005) and Governor of Wisconsin (1987-2001). The Board believes his experience in public service and the healthcare industry makes him well-suited for the role. There are no arrangements or understandings between the Company and Secretary Thompson regarding his selection. The filing notes no recent legal or bankruptcy issues involving Secretary Thompson in the past five years.

Key Facts for Investor Verification

  • Confirm the effective date of Tommy G. Thompson's appointment as Chairman (May 16, 2012).
  • Verify that Robert G. Finizio remains CEO and a director despite stepping down as Chairman.
  • Review Secretary Thompson's current board affiliations, including CareView Communications, C. R. Bard, Centene Corporation, United Therapeutics, and Cytori Therapeutics.
  • Note that this filing does not contain financial data; refer to the most recent 10-Q or 10-K for financial performance.